Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.58 |
| ▸ | PTPRB | P23467 | 1/20 | 0.58 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.58 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703720 | 0.86 | KMT2A (0.66) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30411920 | 0.84 | PTPN2 (0.58) | PTPN2PTPRBPTPN6ABCC1MEN1 | |
| SCHEMBL9291119 | 0.80 | METAP1 (0.50) | MEN1KMT2ASMN1; SMN2PTK2METAP1 | |
| SCHEMBL2928945 | 0.80 | CA12 (0.45) | MEN1KMT2ASMN1; SMN2HPGDMETAP1 | |
| SCHEMBL6969183 | 0.79 | ALDH1A1 (0.44) | PTPN2PTPRBPTPN6MEN1KMT2A | |
| SCHEMBL399013 | 0.79 | METAP1 (0.43) | MEN1KMT2ASMN1; SMN2PTK2METAP1 | |
| SCHEMBL399916 | 0.79 | METAP1 (0.43) | MEN1KMT2ASMN1; SMN2METAP1NPC1 | |
| SCHEMBL5106903 | 0.79 | MAPK10 (0.49) | MEN1KMT2ASMN1; SMN2KDM4EGLA | |
| SCHEMBL544641 | 0.78 | FABP4 (0.52) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL12057624 | 0.78 | ABL1 (0.43) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136129-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET PROTEIN KINASE C | CAPTOR THERAPEUTICS S.A. (PL) | 2025-06-26 | — | — | WO | disclosed |
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4347579-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2024-04-10 | — | — | EP | disclosed |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2023-03-02 | — | — | US | disclosed |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2023-03-02 | — | — | US | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| EP-2441768-A1 | Thienopyrimidinones for treatment of inflammatory disorders and cancers | Eli Lilly & Co. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8084612-B2 | Proline analogs as ligands for cannabinoid receptors | PURDUE PHARMA L.P. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084612-B2 | Proline analogs as ligands for cannabinoid receptors | PURDUE PHARMA L.P. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| CN-101605797-A | The Thienopyrimidinones of treatment inflammatory disease and cancer | LILLY CO ELI (US) | 2009-12-16 | — | — | CN | disclosed |
| US-20090291947-A1 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS | PURDUE PHARMA L.P. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291947-A1 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS | PURDUE PHARMA L.P. (US) | 2009-11-26 | — | — | US | disclosed |
| EP-2097422-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | Eli Lilly & Co. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008064018-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ELI LILLY & CO. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080102068-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080102068-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | PTPN2 3809/4885PTPRB 2107/4885PTPN6 3645/4885 |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | PTPN2 208/4885PTPRB 325/4885PTPN6 268/4885 |
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MCL1, MDM2, XIAP | PTPN2 3657/4885PTPRB 2198/4885PTPN6 3393/4885 |
| US-20090291947-A1 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | PTPN2 1289/4885PTPRB 831/4885PTPN6 1070/4885 |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, FABP7 | PTPN2 3850/4885PTPRB 1948/4885PTPN6 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.